This website uses cookies. By using our website you consent to all cookies in accordance with our Cookie Policy.
AcceptZeus Capital has acted as co-manager to Bone Therapeutics on its €32.2m Euronext Brussels and Euronext Paris IPO, resulting in a market capitalisation of approximately €105 million.
Belgium-based Bone Therapeutics is a leader in bone cell therapy, addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention. The proceeds from the IPO will finance the development of Bone Therapeutics’ innovative bone cell therapy products and consolidate the company’s leadership in bone cell therapy, particularly in fracture repair and fracture prevention.
The transaction was oversubscribed by 2.5x, with 44 per cent of the institutional placement subscribed by Belgian investors and 56 per cent by international investors primarily based in France, the UK, Scandinavia and the Netherlands.
Dominic Wilson, Head of Healthcare at Zeus Capital, said: “Zeus is very pleased to have acted as co-manager to Bryan Garnier on the IPO of Bone Therapeutics on Euronext. Bone Therapeutics has a leading-edge technology with the potential to help meet an unmet medical need in the field of bone fracture repair and fracture prevention. Additionally, this IPO marks Zeus Capital’s first involvement in a listing on Euronext Brussels and Euronext Paris.”
Guild eSports plc
Date: 02 Oct 2020
Sector: Media & Entertainment
Type: IPO
Value: £20m
Mkt Cap Admission: £41.2m
DWF
Date: 15 Mar 2019
Sector: General Retailers
Type: IPO
Value: £95m
Mkt Cap Admission: £366m
Likewise Group plc
Date: 11 Jan 2019
Sector: Household Goods & Home Construction
Type: IPO
Value: £7m
Mkt Cap Admission: £12m
Merian Global Investors
Date: 06 Nov 2018
Sector: Equity Investment Instruments
Type: IPO
Value: £100m
Public Markets
We provide advice to listed and non-listed companies looking to raise capital on public markets.